This site is intended for healthcare professionals

Listen or subscribe on

This podcast series was initiated and fully funded by Sanofi. The content has been reviewed and approved by the sponsoring company and speakers prior to broadcast. Editorial support for this podcast was provided by OmniaMed Communications. GPnotebook has had no input into the content of this podcast series. © 2022 Sanofi

The role of second-generation basal insulins and CGM in optimising glycaemic control: The InRange study (Promotional content from Sanofi)

Diabetes and endocrinology

3 October 2022

MAT-XU-2201780 (v1.0) I August 2022

In this episode, Professor Pratik Choudhary summarises the findings from the InRange study, the first randomised, Phase 4 study to use Time in Range as the primary endpoint to compare second-generation basal insulin analogues, Toujeo (insulin glargine 300 U/mL) and insulin degludec 100 U/mL, in people with type 1 diabetes.¹

Click here to access an on demand webinar video which discusses the InRange study in more detail.

Reference

Battelino T et al. Diabetes Ther 2020;11:1017–1027.

UK Prescribing information for Toujeo^® (insulin glargine 300 U/mL) can be accessed by clicking here.

Republic of Ireland Prescribing information for Toujeo^® (insulin glargine 300 U/mL) can be accessed by clicking here.

Adverse events should be reported.

Great Britain and Northern Ireland reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Sanofi Tel: 0800 090 2314. Alternatively, send via email to [email protected].

Republic of Ireland reporting forms and information can be found at www.hpra.ie; email: [email protected]. Adverse events should also be reported to Sanofi Ireland Ltd. Tel: 01 403 5600. Alternatively, send via email to [email protected].